ArticleNeurology open access2026
Clinical Practice Outcomes With Lecanemab for Alzheimer Disease.
Article in Neurology open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Background and Objectives: Lecanemab, an antiamyloid monoclonal antibody, received US Food and Drug Administration approval in July 2023 to treat amyloid-positive early stages of Alzheimer disease (AD) and has since been adopted in many countries. The primary objective was to assess amyloid-related imaging abnormality (ARIA) incidence and serious adverse events. Secondary objectives included identifying ARIA predictors and evaluating its effect on 12-month cognitive change. Methods: We performed a retrospective, single-site observational study in patients treated with lecanemab at the Duke University (May 2023-June 2025). Eligible patients met National Institute on Aging-Alzheimer's Association criteria for mild cognitive impairment or mild AD with confirmed amyloid pathology. Treatment protocols and MRI interpretations were standardized. Results: Among 230 patients (68% MCI; mean age 73.6; 50.9% female; 67.4% allele producing the ε4 type of apolipoprotein E [ Discussion: Despite the limitations of a single-site cohort, these findings inform real-world lecanemab safety and efficacy. Dual ARIA-E peaks at ~10 and ~25 weeks underscore the need for ongoing MRI monitoring. Although several markers showed modest negative predictive value, none reliably predicted ARIA. Improved markers to predict and monitor ARIA are needed to optimize cognitive outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.